Metraipolis › archive › dc_5de84f101ffa

Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports — Europe PMC PMID:41199832

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41199832
DOI
10.3389/fonc.2025.1647018
License (as archived)
solo-consultazione
Archived
2026-11-09T03:40:34.396Z
SHA-256 of the archived text
494f53556e2b9e61bfa1954f5957dc831e8c85b05274146e94fa2146c7e4cde8
Stable URL of this page
https://metraipolis.com/documento/dc_5de84f101ffa

How to cite

Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports — Europe PMC PMID:41199832 — Europe PMC (en), https://europepmc.org/article/MED/41199832 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_5de84f101ffa (Metraipolis archive dc_5de84f101ffa, sha256 494f53556e2b9e61bfa1954f5957dc831e8c85b05274146e94fa2146c7e4cde8)
BibTeX
@misc{dc5de84f101ffa,
  title = {Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports — Europe PMC PMID:41199832},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41199832},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_5de84f101ffa; sha256 494f53556e2b9e61bfa1954f5957dc831e8c85b05274146e94fa2146c7e4cde8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41199832. Agents can read the archived copy with the MCP tool read_document.